Some investigations of malarial fevers. IV.—The complement fixation reaction

Kingsbury, A. Neave

doi:10.1016/s0035-9203(27)80007-6

Cited by 10 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rather unexpectedly, insight into the immunological basis of cross-reactivity first emerged from attempts to develop species-specific diagnostic tests. In testing the specificity of a complement fixation assay for malaria diagnosis, Kingsbury detected cross-reactivity between P. vivax and P. falciparum antigens (38). Sera from 6 of 12 individuals with acute P. vivax infection reacted to P. falciparum antigens in a precipitin test, and likewise, 5 of 16 sera from patients infected with P. falciparum reacted to P. vivax antigens.…”

Section: Cross-reactive Antibodiesmentioning

confidence: 99%

The Case for Exploiting Cross-Species Epitopes in Malaria Vaccine Design

Mitran

Yanow

2020

Front. Immunol.

View full text Add to dashboard Cite

The infection dynamics between different species of Plasmodium that infect the same human host can both suppress and exacerbate disease. This could arise from inter-parasite interactions, such as competition, from immune regulation, or both. The occurrence of protective, cross-species (heterologous) immunity is an unlikely event, especially considering that strain-transcending immunity within a species is only partial despite lifelong exposure to that species. Here we review the literature in humans and animal models to identify the contexts where heterologous immunity can arise, and which antigens may be involved. From the perspective of vaccine design, understanding the mechanisms by which exposure to an antigen from one species can elicit a protective response to another species offers an alternative strategy to conventional approaches that focus on immunodominant antigens within a single species. The underlying hypothesis is that certain epitopes are conserved across evolution, in sequence or in structure, and shared in antigens from different species. Vaccines that focus on conserved epitopes may overcome the challenges posed by polymorphic immunodominant antigens; but to uncover these epitopes requires approaches that consider the evolutionary history of protein families across species. The key question for vaccinologists will be whether vaccines that express these epitopes can elicit immune responses that are functional and contribute to protection against Plasmodium parasites.

show abstract

Section: Cross-reactive Antibodiesmentioning

confidence: 99%

The Case for Exploiting Cross-Species Epitopes in Malaria Vaccine Design

Mitran

Yanow

2020

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The signs of atabrine poisoning are anorexia, salivation, vomiting, epigastric pain of colicky type, occasional headache and yellowing of the skin (the latter due to the staining properties of the drug and not to liver damage (Kingsbury 1934)). Occasionally psychic disturbances have been reported after administration of relatively small therapeutic doses (6 to 15 tablets) starting within 1% to 9 days after initiation of the treatment and lasting up to several days.…”

Section: Atabrinementioning

confidence: 99%

A Symposium on Human Malaria with Special Reference to North America and the Caribbean Region

1942

JAMA

View full text Add to dashboard Cite

Facilities for blood film diagnosis A few public health labs. Central Lab.: 5 am¬ bulatory clinics since 1937 Government Lab. (Belize) Medical aid in only 16.2% of all deaths 1938 Fruit Company Hos¬ pitals in port cities have good labs. Public Health Labs. (15) & ambulatory clinics Public Health Labs. in San Jose; special surveys Methods of routine diagnosis 14 MALARIA Relative frequency species of malaria plasmodia6 P. falciparum P. vivax P. malariae P. vivax and P. falciparum about equal P. malariae (imported) P. falciparum 90.3% P. vivax 9.2% P. malariae 0.3% P. falciparum 65% P. vivax 32% P. malariae 3% No data; all three species present P. falciparum 55% P. vivax 43 %

show abstract

“…ήταν ένας από τους πρώτους που μελέτησαν τα αντισώματα που συνδέουν το συμπλήρωμα σε ορούς ατόμων που έπα σχαν από ελονοσία χωρίς ωστόσο να καθορίζει το είδος του παράσιτου. ΟKingsbury (1926) χρησιμοποιώντας σαν αντιγόνο το P. Falciparum βρήκε την αντίδραση σύνδεσης συμπληρώματος θετική σε άτομα που είχαν προσβληθεί από P. Vivax. Με ανάλογο τρόπο, αντιγόνο από το Ρ. Vivax έδινε θετική την αντίδραση σύνδεσης συμπληρώματος σε ορούς ατόμων που είχαν προσβληθεί από P. Falciparum.…”

unclassified

Ορο - Επιδημιολογικη Μελετη Της Ελονοσιας Στο Νομο Εβρου

Καραμπινησ¹

View full text Add to dashboard Cite

Some investigations of malarial fevers. IV.—The complement fixation reaction

Cited by 10 publications

References 2 publications

The Case for Exploiting Cross-Species Epitopes in Malaria Vaccine Design

The Case for Exploiting Cross-Species Epitopes in Malaria Vaccine Design

A Symposium on Human Malaria with Special Reference to North America and the Caribbean Region

Ορο - Επιδημιολογικη Μελετη Της Ελονοσιας Στο Νομο Εβρου

Contact Info

Product

Resources

About